Sign inJoin waitlistJoin the waitlist

Jane Meisel

Co-Director, Breast Medical Oncology, Department of Hematology and Medical Oncology · Winship Cancer Institute at Emory Midtown

Credentials: · · · · ·

History

Breast Medical Oncology · Winship Cancer Institute at Emory Midtown
Present
Emory University School of Medicine
Present
Winship Cancer Institute at Emory Midtown · Emory University School of Medicine
Present

Medical Oncology
2012–2014
Internal Medicine
Brigham and Women's Hospital
2008–2011
Harvard Medical School
2004–2008
BA from Harvard College
2000–2004

Research

Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer
Breast Cancer Research and Treatment · 2017 · Last of 9 authors · 425 citations
Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer
Clinical Cancer Research · 2017 · 215 citations
Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
Journal of Clinical Oncology · 2020 · 126 citations

Xiaoxian Li
14 papers
Ruth O’Regan
10 papers
Erica Mayer
9 papers
Kevin Kalinsky
9 papers
Mylin Torres
9 papers
Angela DeMichele
8 papers
Ann Partridge
7 papers
Caitlin Taylor
7 papers · 7 as a resident
Gelareh Sadigh
6 papers
Kathy Miller
6 papers
Sara Tolaney
6 papers
CA
Carol Aghajanian
4 papers

Clinical trials

A Feasibility Trial of a Web Based App Intervention in Hormone Positive Breast Cancer Patients to Improve Adherence to Endocrine Therapy
Principal investigator · Terminated
Emory University
2023–2025
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2023–2033